Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Physiology"
DOI: 10.3389/fphys.2021.738594
Abstract: Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, irrespective of diabetic status. We aimed to investigate the effects of dual SGLT1/2 inhibition, using sotagliflozin,… read more here.
Keywords: cardiac pressure; pressure overload; dual sglt1; mice ... See more keywords